(Q37399992)

20 August 2017

1 reference

title

Immunomodulation in the treatment of haematological malignancies (English)

1 reference

20 August 2017

Michela Cesco-Gaspere

series ordinal

1

1 reference

PubMed ID

19238515

20 August 2017

Emma Morris

series ordinal

2

1 reference

PubMed ID

19238515

20 August 2017

Hans J Stauss

series ordinal

3

1 reference

20 August 2017

24 February 2009

1 reference

Clinical and Experimental Medicine

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

2

1 reference

20 August 2017

81-92

1 reference

https://scigraph.springernature.com/pub.10.1007/s10238-009-0037-1

20 August 2017

0 references

cites work

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10238-009-0037-1

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10238-009-0037-1

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

21 January 2018

1 reference

12 December 2020

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

1 reference

12 December 2020

OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice

1 reference

12 December 2020

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Monoclonal antibodies for B-cell lymphomas: rituximab and beyond

1 reference

12 December 2020

Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation

1 reference

12 December 2020

Immunotherapy for rheumatoid arthritis

1 reference

12 December 2020

Therapy of lymphoma directed at idiotypes

1 reference

12 December 2020

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

1 reference

12 December 2020

Characterization of a human B lymphocyte-specific antigen.

1 reference

12 December 2020

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

1 reference

12 December 2020

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

12 December 2020

FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.

1 reference

12 December 2020

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

12 December 2020

The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions

1 reference

12 December 2020

The clinical use of antibodies in haematological malignancies

1 reference

12 December 2020

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

12 December 2020

Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells

1 reference

12 December 2020

Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes

1 reference

12 December 2020

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

1 reference

12 December 2020

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

12 December 2020

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Use of rituximab, the new FDA-approved antibody.

1 reference

12 December 2020

Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens

1 reference

12 December 2020

Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette

1 reference

12 December 2020

Transfer of specificity by murine alpha and beta T-cell receptor genes

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

12 December 2020

Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

1 reference

12 December 2020

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells

1 reference

12 December 2020

Natural regulatory T cells: mechanisms of suppression

1 reference

12 December 2020

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

1 reference

12 December 2020

Vaccine therapies for non-Hodgkin's lymphoma.

1 reference

12 December 2020

An inducible caspase 9 safety switch for T-cell therapy

1 reference

12 December 2020

Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.

1 reference

12 December 2020

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

1 reference

12 December 2020

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

1 reference

12 December 2020

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

12 December 2020

Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

12 December 2020

Immunogenicity of engineered antibodies

1 reference

12 December 2020

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

12 December 2020

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

12 December 2020

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

12 December 2020

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

1 reference

12 December 2020

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

12 December 2020

Alemtuzumab in the treatment of chronic lymphocytic lymphoma

1 reference

12 December 2020

Immunotherapy through TCR gene transfer

1 reference

12 December 2020

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

1 reference

12 December 2020

Facilitating matched pairing and expression of TCR chains introduced into human T cells

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

1 reference

12 December 2020

Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

1 reference

12 December 2020

Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region

1 reference

12 December 2020

Genetic modification of T lymphocytes for adoptive immunotherapy

1 reference

12 December 2020

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

1 reference

12 December 2020

Restoring function in exhausted CD8 T cells during chronic viral infection

1 reference

12 December 2020

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

12 December 2020

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

12 December 2020

The T-body approach: redirecting T cells with antibody specificity

1 reference

12 December 2020

Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice.

1 reference

12 December 2020

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

1 reference

12 December 2020

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors

1 reference

12 December 2020

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

12 December 2020

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

1 reference

12 December 2020

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

12 December 2020

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 December 2020

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

1 reference

12 December 2020

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 December 2020

Melanoma immunology: past, present and future.

1 reference

12 December 2020

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

1 reference

12 December 2020

A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease

1 reference

12 December 2020

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

1 reference

12 December 2020

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

1 reference

12 December 2020

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

12 December 2020

Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells

1 reference

12 December 2020

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

1 reference

12 December 2020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

12 December 2020

Fully human antibodies from transgenic mouse and phage display platforms

1 reference

12 December 2020

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

1 reference

12 December 2020

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

1 reference

12 December 2020

Engineered antibody Fc variants with enhanced effector function

1 reference

12 December 2020

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 December 2020

Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells

1 reference

12 December 2020

Regulating the immune response to tumours

1 reference

12 December 2020

Selecting and screening recombinant antibody libraries

1 reference

12 December 2020

AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients

1 reference

12 December 2020

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

1 reference

12 December 2020

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

12 December 2020

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

12 December 2020

Novel antibodies as anticancer agents

1 reference

12 December 2020

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

1 reference

12 December 2020

Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

12 December 2020

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

1 reference

12 December 2020

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

1 reference

12 December 2020

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

12 December 2020

10.1007/S10238-009-0037-1

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19238515